20 recruiting, 7 not yet recruiting, 4 unknown, 3 completed. 26 Phase 2, 10 Phase 3, 5 Phase 1, 2 Phase 4.
Follow CAPOX: new trials by email Literature Review of CAPOX trials Research Report on CAPOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer node-sparing modified short-course radiotherapy, standard short-course radiotherapy - Rectal Cancer | Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 210 | 2026-10-25 | 2026-10-28 |
| Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Serplulimab, CAPOX, Bevacizumab - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Xijing Hospital | 85 | 2026-09-01 | 2026-09-15 |
| Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Midhun Malla | 32 | 2026-08-01 | 2026-07-24 |
| Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM SCRT, Retlirafusp alfa Injection, Bevacizumab - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2026-07-30 | 2026-09-22 |
| KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer KRC-01 (KORTUC), Radiotherapy, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 24 | 2026-07-01 | 2026-06-02 |
| Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer Pucotenlimab combine with CAPOX, CAPOX - Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | Recruiting | Sun Yat-sen University | 556 | 2026-04-20 | 2026-04-30 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Recruiting | J. W. A. Burger | 394 | 2026-03-16 | 2026-10-27 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) Pumitamig, Folfox, Capox - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 690 | 2026-03-13 | 2026-09-30 |
| A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ATG-022, pembrolizumab/KEYTRUDA®, CAPOX - Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Antengene Biologics Limited | 132 | 2026-02-27 | 2026-07-29 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-10-23 |
| SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer SIB-SCRT, CAPOX, Immunotherapy - Rectal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 37 | 2025-12-20 | 2025-12-22 |
| SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox - Rectal Cancer, Advanced Stage Colorectal Cancer | Phase 2 | Recruiting | Shandong Provincial Hospital | 208 | 2025-09-12 | 2025-12-16 |
| SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer Short-Course Radiotherapy, Fruquintinib, Tislelizumab - Rectal Neoplasms, Rectal Cancer, Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 50 | 2025-09-11 | 2026-10-22 |
| Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer LCRT, SCRT, CAPOX - Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-01 | 2025-09-04 |
| Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) Capecitabine, Camrelizumab, CAPOX - Locally Advanced Rectal Cancer | Phase 2 | Suspended | Hebei Medical University Fourth Hospital | 90 | 2025-07-01 | 2026-07-31 |
| PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer SHR1701, SHR2554, CAPOX - Advanced Gastric Cancer, SHR1701 | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 78 | 2025-06-15 | 2026-09-01 |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Recruiting | Baylor College of Medicine | 28 | 2025-06-15 | 2025-05-25 |
| Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 228 | 2025-06-01 | 2025-06-26 |
| Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） radiotherapy, CAPOX, Capecitabine - Colon Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 128 | 2025-05-15 | 2026-08-03 |
| Pre-Operative Treatment in REseCTable COlon CanceR mFOLFOXIRI, mFOLFOX-6, CAPOX - Colo-rectal Cancer, Colon Cancer | Phase 3 | Not yet recruiting | Dominik Paul Modest | 714 | 2025-04-01 | 2025-03-28 |
Showing 20 of 39. Sign in to see all of them.
Rectal Neoplasms (14) · Colorectal Neoplasms (8) · Colonic Neoplasms (7) · Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Digestive System Neoplasms (1) · Gastrointestinal Neoplasms (1) · Intestinal Neoplasms (1) · Margins of Excision (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1) · Neoplastic Cells, Circulating (1) · Pathologic Complete Response (1)
Bristol-Myers Squibb (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Dominik Paul Modest (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Hebei Medical University Fourth Hospital (2) · Sun Yat-sen University (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Amgen (1) · Antengene Biologics Limited (1) · Baylor College of Medicine (1) · Canadian Cancer Trials Group (1) · Catharina Ziekenhuis Eindhoven (1) · Erasmus Medical Center (1) · Fondazione Poliambulanza Istituto Ospedaliero (1) · Fudan University (1)
China (16) · United States (8) · France (5) · Germany (5) · Spain (5) · Italy (4) · Japan (4) · Netherlands (4) · Canada (3) · South Korea (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Chile (2)
Atif Iqbal, MD (1) · Carl Brown (1) · Carlos Moreno Sanz (1) · Changqing Jing, Professor (1) · Dominik Modest, Prof. Dr. (1) · Dominik Modest, Prof. Dr. med. (1) · Eduardo Targarona Soler (1) · Evgeny Rybakov, Dr.Med.Sc (1) · Fengpeng Wu (1)
PMID 28497402, PMID 29620995, PMID 32167864, PMID 35366831, PMID 35981270, PMID 36306483, PMID 38412408, PMID 39889251, PMID 39903903, PMID 41812337, PMID 41857556, PMID 42151882, PMID 42736431
2025 (4), 2009 (1), 2019 (1), 2023 (1)